drugset / Trial / NCT00181116

Levetiracetam for Benign Rolandic Epilepsy

NCT00181116

Phase 4 Completed 6 enrolled Johns Hopkins University UCB Pharma · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is designed to test if the language problems commonly seen in children with benign rolandic epilepsy would improve by switching anticonvulsants to levetiracetam.

Timeline

Start
2005-03
Primary completion
Completion
2006-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Levetiracetam Other / unclassified

Indications